Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Join Amanda Maxwell, Regulatory Affairs Editor, David Filmore, Executive Editor, and Ashley Yeo, Principal Analyst of MedTech Insight for a look at medical device (MDR) regulation and the key changes in the US and European medical device markets that are sure to change the industry worldwide in the months and years to come.
Topics covered include an overview of the US and EU medical device regulatory markets and the changes that will take place; the FDA’s shift in focus and how this powerful organization has made improvements in their efficiencies; real-world data and its uses; nascent regulatory mechanisms and key regulatory players; and howmedical device manufacturers must prepare in the face of future regulation of medical devices and IVDs.
The session closes with a discussion of the Dalli Plan of Joint Actions, and an insightful update on the UK and Brexit.
-
Biomedtracker: follow the drug development process
03 Apr 2017
Learn why pharmaceutical, biotech, and investment companies rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.
Scrip: industry news and insights
By Lucie Ellis 22 Feb 2017
Bayer has launched an internal oncology R&D unit to speed up development of its pipeline cancer therapies and ensure the company is first to market with its late-stage treatment candidates, head of pharma Dieter Weinand told Scrip on the sidelines of the pharma's annual results conference.
Biomedtracker: follow the drug development process
What’s on the horizon for pharma in 2018? Find out with Biomedtracker’s Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.
Topics $name
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Report store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
